News for GlaxoSmithKline Consumer Healthcare Ltd. HUL Faces Rs 963 Cr Income Tax Demand: Appeal Planned Hindustan Unilever (HUL) received a Rs 963 crore Income Tax demand for non-deduction of TDS on ...

US pharma major GSK (LSE: GSK) yesterday announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) in adults aged 18-49 at increased risk for RSV-LRTD due ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

GSK's consumer health spinout Haleon started trading on the London Stock Exchange this morning, making its debut with a price of 330 pence and a market valuation of around £31 billion ($37 billion).

Sanofi is aiming to sign an agreement this weekend to sell control of its consumer health business to Clayton Dubilier & Rice, following a last-ditch attempt by a rival bidder to derail the deal ...

Learn More. Often referred to as the Oracle of Omaha, Warren Buffett is one of the most successful investors of all time. He began his road to riches at a young age, using his paper route earnings ...

Real-world evidence show that GSK and ViiV Healthcare’s long-acting pre-exposure prophylaxis Apretude can prevent nearly all HIV infections, while rival Gilead Sciences is moving quickly toward an ...

As Sanofi moves forward with talks to potentially sell a 50% stake its consumer health unit Opella ... Similar events have occurred at GSK and Pfizer, where workers have threatened to temporarily ...

GlaxoSmithKline has filed lawsuits against Moderna in a Delaware federal court, alleging infringement of patents related to mRNA technology in Moderna's COVID-19 vaccine Spikevax and RSV shot mResvia.

GlaxoSmithKline has filed lawsuits against Moderna in the U.S., claiming infringement on its mRNA technology patents with Moderna's COVID-19 vaccine, Spikevax. The legal action, part of a broader web ...

GSK’s consumer healthcare unit was said to be worth $36 billion at the time of the demerger, which was announced in early 2022. CEO Emma Walmsley said the spin out was coming as the U.K. pharma ...